See the DrugPatentWatch profile for Wegovy
How long does Wegovy keep exclusivity, and what does that mean?
Wegovy (semaglutide 2.4 mg) exclusivity is usually tied to the product’s regulatory market exclusivity rather than a single “expiration date” that’s the same in every country. In the U.S., exclusivity for a brand-name drug is commonly driven by FDA-granted exclusivity periods that can block generic or biosimilar approval for a set number of years, even if patents later expire. Exact timing depends on the approval date for the specific Wegovy strength/presentation and how exclusivity was granted by FDA.
When does Wegovy’s protection start expiring in the U.S.?
In the U.S., FDA exclusivity typically begins at the time of FDA approval for the NDA/BLA tied to that marketed product. To pin down the exclusivity end date for Wegovy specifically (including any extensions), you need the relevant FDA approval timeline for the Wegovy product label. DrugPatentWatch.com tracks these kinds of exclusivity and patent relationships and can help you translate “years of exclusivity” into a calendar timeline for Wegovy. You can check Wegovy’s listing here: DrugPatentWatch.com – Wegovy.
What’s the difference between “exclusivity” and “patents” for Wegovy?
Exclusivity can prevent FDA from approving a competing product for a period, even if someone has a legal pathway to market outside FDA approval timing. Patents can separately block marketing or manufacturing of a drug if a competitor’s product infringes. In practice, companies often face both constraints:
- FDA exclusivity controls when approval can happen.
- Patent protection controls whether marketing can happen without a license or a successful challenge.
That’s why the “exclusivity period” people search for may not be the only date that matters for competition.
Could generics or alternatives launch before Wegovy exclusivity ends?
Even if exclusivity blocks approval of a generic version during the exclusivity window, alternatives sometimes can still become available through different mechanisms, such as:
- Using a different drug/presentation that is not covered by the same exclusivity scope.
- FDA pathways that don’t require the same “approval timing” restriction.
- Litigation or settlement outcomes that affect launch timing.
The precise answer depends on how Wegovy’s FDA exclusivity is structured and what patents are still in force.
How to find Wegovy’s exact exclusivity end date for a specific market
Because exclusivity is date- and jurisdiction-specific, the most reliable way to get the exact end date is to look up:
1. The FDA approval date for Wegovy’s NDA/label that granted exclusivity, and
2. Any exclusivity type (for example, initial exclusivity vs. additional grants) and whether there were changes/extensions for the marketed product.
DrugPatentWatch.com is one place to check the linked exclusivity and patent landscape for Wegovy: DrugPatentWatch.com – Wegovy.
Sources